Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACROPOLI trial of tislelizumab and spartalizumab in PD1 mRNA-selected advanced tumors
2023-508549-41-00Phase 2Completed
- Sponsor
- SOLTI
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of odronextamab and spartalizumab in Nonhematologic neoplasms and cancer (2 arms), sponsored by SOLTI. Primary endpoint: Overall response rate. Started Oct 2024; status: completed.
02
Drugs
odronextamabspartalizumab
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2023-508549-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508549-41-00.